Physician profile
David Arther Van
NPI 1851452254
$9,459.04
in general payments reported to CMS, 2019-2025
47 companies · $1,765 in 2025
The $1,765 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,125 · 2020: $828 · 2021: $1,089 · 2022: $1,192 · 2023: $1,997 · 2024: $1,463 · 2025: $1,765.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,225.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,495.71 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,071.07 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $748.97 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $711.23 | 2019-2025 | |
| Lilly USA, LLC | $689.16 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $666.65 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $601.75 | 2019-2025 | Otezla, Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $431.40 | 2021-2025 | Rexulti |
| Merz North America, INC. | $390.76 | 2022-2023 | Xeomin |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $243.98 | 2022-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $220.29 | 2019-2024 | Tradjenta, Synjardy, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $203.31 | 2021-2025 | |
| Allergan, INC. | $191.46 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $180.14 | 2019-2023 | Xifaxan, Trulance |
| Astellas Pharma US INC | $161.42 | 2019-2024 | Veozah |
Show all 46 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Van listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.